Top Clicks This Month

1,3,5-Tri-o-acetyl-2-deoxy-α-D-erythro-pentoFuranose - CAS 96291-74-6

Quick Inquiry

Name:
* Email:
* Service & Products of Interest:
* Quantity:
* Verification code:
Please input "bocsci" as verification code.
Category
Main Product
Product Name
1,3,5-Tri-o-acetyl-2-deoxy-α-D-erythro-pentoFuranose
Catalog Number
96291-74-6
Synonyms
1,3,5-TRI-O-ACETYL-2-DEOXY-ALPHA-D-ERYTHRO-PENTOFURANOSE;A-D-ERYTHRO-PENTOFURANOSE
CAS Number
96291-74-6
Molecular Weight
260.24
Molecular Formula
C11H16O7
COA
Inquire
MSDS
Inquire
Structure
CAS 96291-74-6 1,3,5-Tri-o-acetyl-2-deoxy-α-D-erythro-pentoFuranose
Specification
Purity
98%
Boiling Point
329.3ºC at 760 mmHg
Density
1.24g/cm3
Reference Reading
1.Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan.
Koh K1, Ogawa C2,3, Okamoto Y4, Kudo K5,6, Inagaki J7, Morimoto T8, Mizukami H9, Ecstein-Fraisse E9, Kikuta A10. Int J Hematol. 2016 Apr 16. [Epub ahead of print]
A phase 1 study was conducted to evaluate the safety, pharmacokinetics (PK), efficacy and pharmacogenetic characteristics of clofarabine in seven Japanese pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL). Patients in Cohort 1 received clofarabine 30 mg/m2/day for 5 days, followed by 52 mg/m2/day for 5 days in subsequent cycles. Cohort 2 patients were consistently treated with 52 mg/m2/day for 5 days. No more than six cycles were performed. Every patient had at least one ≥Grade 3 adverse event (AE). AEs (≥Grade 3) related to clofarabine were anaemia, neutropenia, febrile neutropenia, thrombocytopenia, alanine aminotransferase increased, aspartate aminotransferase increased, haemoglobin decreased, and platelet (PLT) count decreased. C max and AUC of clofarabine increased in a dose-dependent fashion, but its elimination half-life (T 1/2) did not appear to be dependent on dose or duration of treatment. Clofarabine at 52 mg/m2/day shows similarly tolerable safety and PK profiles compared to those in previous studies.
2.Clinical and socioeconomic impact of moderate-to-severe versus mild influenza in children.
Heikkinen T1,2, Silvennoinen H3, Heinonen S3,4, Vuorinen T5,6. Eur J Clin Microbiol Infect Dis. 2016 Apr 16. [Epub ahead of print]
Some studies have assessed the efficacy of influenza vaccination in children separately for moderate-to-severe and any influenza, but the definition used for identifying children with moderate-to-severe illness has not been validated. We analyzed clinical and socioeconomic data from two prospective cohort studies of respiratory infections among children aged ≤13 years (four influenza seasons, 3,416 child-seasons of follow-up). We categorized children with laboratory-confirmed influenza into two mutually exclusive groups of moderate-to-severe and mild influenza using the previously proposed criteria. We obtained the data for the analyses from structured medical records filled out by the study physicians and from daily symptom cards filled out by the parents. Of 434 cases of influenza, 217 (50 %) were classified as moderate-to-severe and 217 (50 %) as mild. The mean duration of fever was 4.0 days in children with moderate-to-severe influenza and 3.
3.Editorial.
Dudek D1, Sobański JA2, Klasa K3. Psychiatr Pol. 2016;50(1):3-4. doi: 10.12740/PP/60821.
no summary.
4.Childhood adversity as a moderator of the relationship between emotional reactivity and the occurrence of anxiety and depression in a non-clinical group.
Dragan WŁ1, Zielińska A1, Zagdańska M2. Psychiatr Pol. 2016;50(1):95-104. doi: 10.12740/PP/40064.
OBJECTIVES: The research is an attempt to confirm the role of emotional reactivity and childhood adversity in the development of anxiety and depression as well as to determine the scope of interaction between these two factors.
2005 - BOC Sciences | All rights reserved
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE